Table 1. Progression-free survival and overall survival in phase III studies for stage III, unresectable NSCLC.
| Study | Median PFS (months) | 12 m-PFS | 24 m-PFS | Median OS (months) | 12 m-OS | 24 m-OS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STD | EXP | STD | EXP | STD | EXP | STD | EXP | STD | EXP | STD | EXP | ||||||
| PACIFIC (2017, 2018) (27,28) | 5.6 | 16.8 | 35.3% | 55.9% | 27.0% (†18 m) | 44.2% (†18 m) | 28.7 | NR | 75.3% | 83.1% | 55.6% | 66.3% | |||||
| PROCLAIM (2016) (10) | 9.8 | 11.4 | – | – | – | – | 25.0 | 26.8 | 77% | 76% | 52% | 52% | |||||
| RTOG 0617 (2015) (5) | 11.8 | 9.8 | 49.2% | 41.2% | 29.1% | 21.4% | 28.7 | 20.3 | 80.0% | 69.8% | 57.6% | 44.6% | |||||
†, 18 months instead of 24 months. NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; STD, standard arm; EXP, experimental arm; NR, not reached.